Willis Towers Watson Price Targets Raised to $379 and $400 on Strong Segment Growth
Analyst Elyse Greenspan raised her Overweight target to $379, implying 32% upside, while Mark Hughes raised his Buy target to $400, implying 39% upside. Both cited mid- to high-single-digit organic growth in the Risk & Broking segment and mid-single-digit growth in Health, Wealth & Career after Q4 results outperformed consensus estimates.
1. Analyst Ratings and Price Target Increases
Analyst Elyse Greenspan maintained an Overweight rating and increased her price target from $366 to $379, signaling a 32% upside potential. Mark Hughes also reaffirmed a Buy rating and lifted his target from $380 to $400, reflecting a 39% upside forecast.
2. Segment Performance and Outlook
Both analysts highlighted the Corporate Risk & Broking segment’s organic growth outlook of mid- to high-single digits. They further noted the Health, Wealth & Career segment is projected to deliver mid-single-digit growth, underpinning the company’s diversified revenue streams.
3. Q4 Earnings Performance
Willis Towers Watson’s fourth-quarter results surpassed consensus estimates, driven by robust brokerage revenues and efficient risk solutions execution. The stronger-than-expected results prompted positive market reactions and reinforced management’s optimistic guidance.
4. Company Overview
Willis Towers Watson is a global advisory, broking and risk management firm offering actuarial support, strategy consulting, plan administration and benefit program services across life, medical, disability and voluntary products.